Advanced search
1 file | 1.00 MB Add to list

Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses

Ans De Beuckelaer (UGent) , Charlotte Pollard (UGent) , Sandra Van Lint (UGent) , Kenny Roose (UGent) , Lien Van Hoecke (UGent) , Tom Naessens (UGent) , Vimal Kumar Udhayakumar (UGent) , Muriel Smet (UGent) , Niek Sanders (UGent) , Stefan Lienenklaus, et al.
(2016) MOLECULAR THERAPY. 24(11). p.2012-2020
Author
Organization
Abstract
Given their high potential to evoke cytolytic T cell responses, tumor antigen-encoding messenger RNA (mRNA) vaccines are now being intensively explored as therapeutic cancer vaccines. mRNA vaccines clearly benefit from wrapping the mRNA into nano-sized carriers such as lipoplexes that protect the mRNA from degradation and increase its uptake by dendritic cells in vivo. Nevertheless, the early innate host factors that regulate the induction of cytolytic T cells to mRNA lipoplex vaccines have remained unresolved. Here, we demonstrate that mRNA lipoplexes induce a potent type I interferon (IFN) response upon subcutaneous, intradermal and intranodal injection. Regardless of the route of immunization applied, these type I IFNs interfered with the generation of potent cytolytic T cell responses. Most importantly, blocking type I IFN signaling at the site of immunization through the use of an IFNAR blocking antibody greatly enhanced the prophylactic and therapeutic antitumor efficacy of mRNA lipoplexes in the highly aggressive B16 melanoma model. As type I IFN induction appears to be inherent to the mRNA itself rather than to unique properties of the mRNA lipoplex formulation, preventing type I IFN induction and/or IFNAR signaling at the site of immunization might constitute a widely applicable strategy to improve the potency of mRNA vaccination.
Keywords
DENDRITIC CELLS, PROSTATE-CANCER, IFN-ALPHA, VACCINATION, ACTIVATION, DELIVERY, CD8(+), LYMPHOCYTES, EFFICACY, IMMUNITY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.00 MB

Citation

Please use this url to cite or link to this publication:

MLA
De Beuckelaer, Ans et al. “Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.” MOLECULAR THERAPY 24.11 (2016): 2012–2020. Print.
APA
De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V. K., et al. (2016). Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses. MOLECULAR THERAPY, 24(11), 2012–2020.
Chicago author-date
De Beuckelaer, Ans, Charlotte Pollard, Sandra Van Lint, Kenny Roose, Lien Van Hoecke, Tom Naessens, Vimal Kumar Udhayakumar, et al. 2016. “Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.” Molecular Therapy 24 (11): 2012–2020.
Chicago author-date (all authors)
De Beuckelaer, Ans, Charlotte Pollard, Sandra Van Lint, Kenny Roose, Lien Van Hoecke, Tom Naessens, Vimal Kumar Udhayakumar, Muriel Smet, Niek Sanders, Stefan Lienenklaus, Xavier Saelens, Siegfried Weiss, Guido Vanham, Johan Grooten, and Stefaan De Koker. 2016. “Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.” Molecular Therapy 24 (11): 2012–2020.
Vancouver
1.
De Beuckelaer A, Pollard C, Van Lint S, Roose K, Van Hoecke L, Naessens T, et al. Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses. MOLECULAR THERAPY. 2016;24(11):2012–20.
IEEE
[1]
A. De Beuckelaer et al., “Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses,” MOLECULAR THERAPY, vol. 24, no. 11, pp. 2012–2020, 2016.
@article{8052334,
  abstract     = {Given their high potential to evoke cytolytic T cell responses, tumor antigen-encoding messenger RNA (mRNA) vaccines are now being intensively explored as therapeutic cancer vaccines. mRNA vaccines clearly benefit from wrapping the mRNA into nano-sized carriers such as lipoplexes that protect the mRNA from degradation and increase its uptake by dendritic cells in vivo. Nevertheless, the early innate host factors that regulate the induction of cytolytic T cells to mRNA lipoplex vaccines have remained unresolved. Here, we demonstrate that mRNA lipoplexes induce a potent type I interferon (IFN) response upon subcutaneous, intradermal and intranodal injection. Regardless of the route of immunization applied, these type I IFNs interfered with the generation of potent cytolytic T cell responses. Most importantly, blocking type I IFN signaling at the site of immunization through the use of an IFNAR blocking antibody greatly enhanced the prophylactic and therapeutic antitumor efficacy of mRNA lipoplexes in the highly aggressive B16 melanoma model. As type I IFN induction appears to be inherent to the mRNA itself rather than to unique properties of the mRNA lipoplex formulation, preventing type I IFN induction and/or IFNAR signaling at the site of immunization might constitute a widely applicable strategy to improve the potency of mRNA vaccination.},
  author       = {De Beuckelaer, Ans and Pollard, Charlotte and Van Lint, Sandra and Roose, Kenny and Van Hoecke, Lien and Naessens, Tom and Udhayakumar, Vimal Kumar and Smet, Muriel and Sanders, Niek and Lienenklaus, Stefan and Saelens, Xavier and Weiss, Siegfried and Vanham, Guido and Grooten, Johan and De Koker, Stefaan},
  issn         = {1525-0016},
  journal      = {MOLECULAR THERAPY},
  keywords     = {DENDRITIC CELLS,PROSTATE-CANCER,IFN-ALPHA,VACCINATION,ACTIVATION,DELIVERY,CD8(+),LYMPHOCYTES,EFFICACY,IMMUNITY},
  language     = {eng},
  number       = {11},
  pages        = {2012--2020},
  title        = {Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses},
  url          = {http://dx.doi.org/10.1038/mt.2016.161},
  volume       = {24},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: